Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Monopar Therapeutics changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 9 | 13 | +4 |
| Shares | 198.4K | 204.2K | +5.87K (+3.0%) |
| Value | $964.4K | $657.2K | −$307.2K (−31.8%) |
New holders (4)
Institutions that held Monopar Therapeutics at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 3,067 | $10.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,401 | $8.00K | 0.00% |
| FinTrust Capital Advisors, LLC | 500 | $2.00K | 0.00% |
| Bank of America Corp | 7 | $0 | 0.00% |
Sold out (0)
Institutions that held Monopar Therapeutics at the end of Q3 2021 and filed for Q4 2021 without it.
None.